S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis|
|Galectin Therapeutics Issues Statement on GR-MD-02 Development Program|
|Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis|
|EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Galectin Therapeutics, Inc. -- GALT|
|SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT|
|Galectin Therapeutics Added to Russell 2000 Index|
|Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Galectin Therapeutics, Inc. (GALT) to Contact the Firm|
|Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma|
|Ryan & Maniskas, LLP Announces Investigation of Galectin Therapeutics, Inc.|
|Harwood Feffer LLP Announces Investigation of Galectin Therapeutics Inc.|
Click above to view more mutual fund data and stats for galt - Galectin Therapeutics Inc.